b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30820060</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>13</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>06</Month>\n            <Day>13</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Print">0386-300X</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>73</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Feb</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Acta medica Okayama</Title>\n                <ISOAbbreviation>Acta Med. Okayama</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Conventional-dose Versus Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Disease: A Non-blind, Randomized Controlled Trial.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>85-89</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.18926/AMO/56464</ELocationID>\n            <Abstract>\n                <AbstractText>Pneumocystis pneumonia (PCP) due to Pneumocystis jirovecii infection is the leading cause of fatal opportunistic infections in immunocompromised patients. We will determine whether a daily sulfamethoxazole-trimethoprim (SMX/TMP) dose of 200/40 mg was non-inferior to 400/80 mg for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the rate of PCP prevention at 52 weeks. The secondary outcome is the discontinuation rate of SMX/TMP. The trial will evaluate the optimal dose of SMX/TMP for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Abe</LastName>\n                    <ForeName>Yoshiyuki</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fujibayashi</LastName>\n                    <ForeName>Kazutoshi</ForeName>\n                    <Initials>K</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nishizaki</LastName>\n                    <ForeName>Yuji</ForeName>\n                    <Initials>Y</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yanagisawa</LastName>\n                    <ForeName>Naotake</ForeName>\n                    <Initials>N</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nojiri</LastName>\n                    <ForeName>Shuko</ForeName>\n                    <Initials>S</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nakano</LastName>\n                    <ForeName>Soichiro</ForeName>\n                    <Initials>S</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tada</LastName>\n                    <ForeName>Kurisu</ForeName>\n                    <Initials>K</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yamaji</LastName>\n                    <ForeName>Ken</ForeName>\n                    <Initials>K</Initials>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tamura</LastName>\n                    <ForeName>Naoto</ForeName>\n                    <Initials>N</Initials>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Japan</Country>\n            <MedlineTA>Acta Med Okayama</MedlineTA>\n            <NlmUniqueID>0417611</NlmUniqueID>\n            <ISSNLinking>0386-300X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>8064-90-2</RegistryNumber>\n                <NameOfSubstance UI="D015662">Trimethoprim, Sulfamethoxazole Drug Combination</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011020" MajorTopicYN="N">Pneumonia, Pneumocystis</DescriptorName>\n                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015662" MajorTopicYN="N">Trimethoprim, Sulfamethoxazole Drug Combination</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">conventional-dose versus half-dose</Keyword>\n            <Keyword MajorTopicYN="N">pneumocystis pneumonia</Keyword>\n            <Keyword MajorTopicYN="N">prophylaxis</Keyword>\n            <Keyword MajorTopicYN="N">sulfamethoxazole-trimethoprim</Keyword>\n            <Keyword MajorTopicYN="N">systemic rheumatic disease</Keyword>\n        </KeywordList>\n        <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>2</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>2</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>14</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30820060</ArticleId>\n            <ArticleId IdType="doi">10.18926/AMO/56464</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'